SCHEMBL14724832

SCHEMBL14724832

CNC(=O)CCc1cccc(C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ HDAC3 O15379 1/20 0.52
▸ HDAC1 Q13547 1/20 0.52
▸ HDAC2 Q92769 1/20 0.52
▸ HDAC10 Q969S8 1/20 0.52
▸ HDAC11 Q96DB2 1/20 0.52
▸ HDAC8 Q9BY41 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ MAPT P10636 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ TAAR1 Q96RJ0 1/20 0.50
▸ RAB9A P51151 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19540907 0.83 MTNR1A (0.48) ALDH1A1HDAC3HDAC2HDAC8HDAC6
SCHEMBL16015432 0.83 MAPT (0.48) ALDH1A1HDAC3HDAC1HDAC2HDAC10
Dimethylamine SCHEMBL9871069 0.83 FFAR4 (0.62) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL13329815 0.82 L3MBTL1 (0.56) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL18086761 0.82 SMN1; SMN2 (0.58) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL17054178 0.82 MEN1 (0.52) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL7337631 0.82 TAAR1 (0.57) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL19182347 0.81 FFAR1 (0.49) ALDH1A1KDM4EHDAC1HDAC2HDAC8
SCHEMBL30559640 0.81 TAAR1 (0.57) MEN1KMT2AALDH1A1LMNAHDAC1
SCHEMBL14548815 0.81 MAOA (0.50) ALDH1A1HDAC2HDAC8HDAC6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177443-A1 SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-06-09 — — US disclosed
WO-2017190107-A1 SIGMA RECEPTOR BINDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-11-02 — — WO disclosed
WO-2017158136-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR ORYZON GENOMICS, S.A. (ES) 2017-09-21 — — WO disclosed
EP-1523473-B1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2013-02-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177443-A1 SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE IKZF2, IKZF1, IKZF3 MEN1 2835/4885KMT2A 537/4885ALDH1A1 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback